Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...
Pfizer's decision could stem from the fairly dismal performance of the only gene therapy for haemophilia A currently on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback